Zacks: Analysts Anticipate 2seventy bio, Inc. (NASDAQ:TSVT) Will Announce Quarterly Sales of $24.45 Million

Equities analysts expect 2seventy bio, Inc. (NASDAQ:TSVTGet Rating) to announce sales of $24.45 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for 2seventy bio’s earnings, with the lowest sales estimate coming in at $13.20 million and the highest estimate coming in at $37.09 million. The business is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that 2seventy bio will report full-year sales of $95.01 million for the current year, with estimates ranging from $65.31 million to $128.86 million. For the next year, analysts expect that the business will report sales of $116.87 million, with estimates ranging from $89.58 million to $142.37 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow 2seventy bio.

2seventy bio (NASDAQ:TSVTGet Rating) last issued its quarterly earnings data on Tuesday, March 22nd. The company reported ($2.55) EPS for the quarter, topping analysts’ consensus estimates of ($2.73) by $0.18.

A number of equities research analysts have recently commented on TSVT shares. Zacks Investment Research raised shares of 2seventy bio from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Saturday, March 26th. Cowen assumed coverage on shares of 2seventy bio in a research note on Thursday, January 6th. They set an “outperform” rating on the stock. Finally, SVB Leerink assumed coverage on shares of 2seventy bio in a research note on Thursday, February 10th. They issued an “outperform” rating and a $38.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $42.40.

Shares of NASDAQ TSVT opened at $13.80 on Thursday. 2seventy bio has a 12 month low of $11.43 and a 12 month high of $64.00. The stock’s 50 day moving average price is $15.35.

In related news, COO Nicola Heffron sold 1,636 shares of 2seventy bio stock in a transaction on Monday, February 7th. The shares were sold at an average price of $16.01, for a total value of $26,192.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

2seventy bio Company Profile (Get Rating)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.

Read More

Get a free copy of the Zacks research report on 2seventy bio (TSVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for 2seventy bio (NASDAQ:TSVT)

Want More Great Investing Ideas?

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.